EGFR L792H与G796R:介导第三代EGFR酪氨酸激酶抑制剂奥希替尼耐药的两个新突变
该研究对340例接受奥希替尼治疗的肺腺癌患者进行二代测序,筛查L792H和G796R突变频率,并构建Ba/F3细胞模型及进行结构分析。L792H和G796R分别见于1.76%(6/340)和0.56%(2/340)的患者,在L858R/T790M背景下引入任一突变均导致奥希替尼敏感性显著下降,且多种药物组合(包括西妥昔单抗联合EAI045)未能有效抑制。
要点
- 奥希替尼治疗肺腺癌患者中L792H突变频率为1.76%(6/340),G796R为0.56%(2/340)。
- L858R/T790M/L792H和L858R/T790M/G796R突变在体外和计算机模拟中均导致奥希替尼耐药。
- 针对低频耐药突变,需更精准的治疗策略和额外的联合方案。
核心结论
- EGFR L858R/T790M/L792H和L858R/T790M/G796R突变在体外和计算机模拟中均赋予对奥希替尼的耐药性。
研究设计与样本
- 对340例接受奥希替尼治疗的肺腺癌患者DNA样本进行二代测序,筛查L792H和G796R突变频率。
- 构建稳定表达EGFR L858R/T790M(顺式)伴L792H或G796R突变的Ba/F3细胞,体外评估对EGFR酪氨酸激酶抑制剂及潜在药物组合的敏感性。
- 使用Schrödinger/Maestro软件(版本11.1.012)进行结构分析。
主要发现
- L792H和G796R分别见于1.76%(6/340)和0.56%(2/340)接受奥希替尼治疗的肺腺癌患者。
- 在L858R/T790M背景中引入L792H或G796R突变导致奥希替尼敏感性大幅降低。
- 结构建模显示,与T790M顺式的突变迫使奥希替尼旋转出去(破坏结合)或牵拉铰链环(破坏铰链)。
- 包括西妥昔单抗联合EAI045在内的多种其他药物组合均未能有效抑制任一顺式突变。
临床怎么用
- 对于奥希替尼治疗后出现L792H或G796R突变的患者,需考虑耐药可能并探索更精准的治疗策略。
- 针对低频耐药突变,可能需要额外的联合治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The third-generation EGFR tyrosine kinase inhibitor osimertinib has been approved in many countries to treat advanced NSCLC in patients with the EGFR T790M mutation. As the development of acquired resistance is inevitable, it is urgent that the mechanisms of such resistance be clarified. METHODS: DNA samples from a cohort of 340 patients with lung adenocarcinoma who were taking osimertinib were subjected to next-generation sequencing and screened in terms of the frequencies of the L792H and G796R mutations. Ba/F3 cells stably expressing the EGFR L858R/T790M mutations (in cis) with either the L792H or G796R mutation were created to investigate the impact of the two novel mutations on EGFR tyrosine kinase inhibitors and other potential drug combinations in vitro. Structural analyses were performed by using Schrödinger/Maestro software (version 11.1.012, Schrödinger LLC, Cambridge, MA). RESULTS: L792H and G796R were detected in 1.76% (six of 340) and 0.56% (two of 340) patients with lung adenocarcinoma treated with osimertinib, respectively. The introduction of L792H or G796R mutations against an L858R/T790M background caused dramatic reductions in osimertinib sensitivity. Structural modeling showed that mutations in cis with T790M either forced the ligand (osimertinib) to rotate out (breaking the binding) or pulled the hinge loop (breaking the hinge). Various other drug combinations. including cetuximab with EAI045, failed to inhibit either cis mutant effectively. CONCLUSIONS: The EGFR L858R/T790M/L792H and L858R/T790M/G796R mutations conferred resistance to osimertinib both in vitro and in silico. For patients in whom the two resistance mutations occur at low frequency, more precise treatment strategies and additional combinational approaches are required.
引用
- Zhang Q, Zhang XC, Yang JJ, et al. EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib. J Thorac Oncol. 2018. PMID: 29857056. doi:10.1016/j.jtho.2018.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。